• OnShift

  Participated · Series D · Apr 2016

  OnShift is a Cleveland, Ohio-based developer of human capital management software for the long-term, post-acute care market. Santa Monica-based private equity investor Clearlake Capital led a strategic funding round in the company. Financial details of the strategic investment were not disclosed in the article. The provided article text is behind a paywall and cuts off before OnShift's full statement on the funding. No operating metrics, valuation, or use-of-proceeds were included in the available text. OnShift is a Cleveland, OH-based provider of cloud-based human capital management software and services for the healthcare industry. Led by CEO Mark Woodka, the company offers products for hiring, scheduling and workforce analysis tailored to post-acute care and senior living providers. Its offerings combine software and services to support hiring, workforce scheduling and analysis. Clients named in the article include Senior Living Communities, HCF Management, Altercare and Friendship Village. OnShift closed an $18M Series D and intends to use the funds to expand product development and accelerate sales and marketing. OnShift offers SaaS and mobile staff scheduling and labor management software designed for long-term care and senior living providers. Its platform predicts and prevents overtime and understaffing, reduces time spent on scheduling and managing open shifts, and integrates with time-keeping, HR, clinical, and payroll systems. The company reports growth to over 1,000 customer sites in the past year. Market demand has been driven by Medicare and Medicaid reimbursement cuts, Affordable Care Act changes, and an aging population, which have increased provider focus on labor costs. OnShift plans to use new financing to accelerate research and development and expand sales and marketing to increase its presence in the healthcare market. Management positions the product as an easy-to-use scheduling solution with a tightly integrated communications platform that delivers fast ROI. OnShift develops web-based staff scheduling and shift management software for long-term care and senior living providers. Led by CEO Mark Woodka and based in Cleveland, OH, the product integrates with time-keeping, HR, clinical and payroll systems. It helps customers control labor costs by preventing overtime, managing open shifts and maintaining appropriate staffing levels. The software predicts and prevents overtime and understaffing while dramatically reducing time spent on scheduling and managing open shifts. The company plans to use new capital to accelerate sales and marketing and expand its presence in the healthcare industry. OnShift offers web-based staff scheduling and shift management software for long-term care companies and other healthcare organizations. Its platform is designed to reduce labor costs by preventing overtime, mitigate regulatory compliance risk, and improve efficiencies through automated scheduling and open shift management. The company is Cleveland, Ohio–based and serves healthcare employers seeking to optimize workforce scheduling. OnShift closed a $2.3M venture capital financing to support its growth. The company intends to use the funds to accelerate sales and marketing efforts and increase its market share in the healthcare industry. In conjunction with the funding, Michael Stubler of Draper Triangle Ventures will join OnShift’s Board of Directors.

• HistoSonics

  Participated · Equity · Sep 2015

  HistoSonics develops a non-invasive therapeutic platform based on histotripsy, a focused-ultrasound technology that uses acoustic cavitation to mechanically destroy and liquefy targeted tissue. Its flagship product, the Edison® Histotripsy System, received U.S. FDA De Novo clearance for the destruction of liver tumors and has seen expanding clinical adoption at academic medical centers and health systems. Use of the system outside the liver remains investigational while the company pursues regulatory clearances for additional organs. HistoSonics has submitted a De Novo request to the FDA for kidney tumors and is advancing toward an anticipated FDA submission for pancreatic applications. The company is focused on commercializing the Edison System in the U.S. and select global markets while expanding indications into kidney, pancreas, prostate and other organs. HistoSonics maintains offices in Ann Arbor, MI, Madison, WI, and Minneapolis, MN, and was valued at $3.75 billion in its most recent financing.

• Amplifinity

  Participated · Equity · Jan 2013

  Amplifinity develops the Advocacy Management Platform (AMP), a social marketing solution used by enterprise customers to generate referrals, endorsements, and amplified marketing through customers, employees, and third parties. AMP is positioned to lower customer acquisition costs compared with traditional channels and to improve revenue, retention, and profitability for brands. The company reports a quickly growing client roster, expanding technical capabilities, and strategic executive hires in 2012/13. Amplifinity is a member of the Word of Mouth Marketing Association (WOMMA) and highlights enterprise adoption of its platform. The company is based in Ann Arbor, Michigan. Recent financing activity from state and venture partners is intended to extend its runway and support continued product and commercial growth. Amplifinity, formerly known as uRefer, develops a word-of-mouth and brand advocacy marketing technology called an Advocate Management Platform. The platform helps clients identify brand advocates, grow their consumer base, and create wide-reaching social campaigns driven by customer recommendations. The company serves marketing agencies and a range of clients across industries including home goods and services, banking, hospitality and entertainment. Founded in 2007 and led by CEO Paul Vlasic, Amplifinity is based in Ann Arbor, Michigan. It closed a $2.5M Series A to accelerate growth, enhance its technology, and expand its client base. The article does not disclose revenue or user metrics.

• Juventas Therapeutics

  Participated · Series B · Jul 2012

  Juventas Therapeutics is focused on developing non-viral gene therapies for advanced cardiovascular diseases, with its lead candidate JVS-100 undergoing evaluation in clinical studies. JVS-100 is being developed under an exclusive license from the Cleveland Clinic. The company was founded in 2007 and is based in Cleveland, Ohio, and is led by president and CEO Rahul Aras, Ph.D. Juventas recently expanded its Board of Directors with the addition of James Boland. Financially, the company secured a financing package comprising equity and debt to support its clinical-stage programs. The financing details indicate a mix of Series B-2 equity and debt with milestone-linked additional capital available. Juventas Therapeutics, founded in 2007 and led by President & CEO Rahul Aras, Ph.D., is a Cleveland, OH-based clinical-stage regenerative medicine company advancing JVS-100, its lead product encoding Stromal cell‑Derived Factor 1 (SDF‑1). JVS-100 has been shown to repair damaged tissue by recruiting circulating stem cells to sites of injury, preventing ongoing cell death, and restoring blood flow. The company closed a $22.2M Series B financing and intends to use the funds to complete ongoing Phase II clinical trials. The Phase II trials are investigating JVS-100 in patients with chronic heart failure and critical limb ischemia, and both trials are actively enrolling. The financing supports continued clinical development of the therapy and associated programs.

• CytoPherx

  Led · Equity · Jan 2012

  CytoPherx develops a proprietary Selective Cytopheretic Device (SCD) that is added to the renal replacement circuit to modulate acute systemic inflammation in ICU patients with kidney injury. The company is clinical-stage and pursuing U.S. regulatory approval to commercialize its anti-inflammatory therapy for acute kidney injury. Management reports early trials showing potential mortality reductions of as much as 15% in critically ill patients. CytoPherx has initiated a 344-patient pivotal trial across leading U.S. nephrologists and institutions, with a primary endpoint of reduced mortality through day 60 and secondary evaluations including severe sepsis, ARDS, and long-term dialysis dependence. The company says the target population represents over 2.7 million hospitalized U.S. patients diagnosed with acute renal failure annually, with roughly 160,000 receiving Continuous Renal Replacement Therapy, a multi-billion dollar market opportunity. CytoPherx was founded in July 2007 and is headquartered in Ann Arbor, Michigan. CytoPherx develops hollow-fiber dialysis filters designed to isolate and deactivate white blood cells in patients’ bloodstreams to treat renal failure and inflammation from cardiopulmonary bypass. The company is a University of Michigan spinoff, founded in 2007 and previously known as Nephrion Inc., based in Ann Arbor, Mich. The recent funding will support a clinical trial for its filters; CytoPherx began enrolling patients last month and expects to complete enrollment by the end of June. The current financing is part of an anticipated $7.5M Series B, with $5M already raised. The new funds are structured as equity, debt and warrants and were sourced from five investors. To date, the company has raised $12M in total lifetime funding.

No current team members are available.